Chemomab Therapeutics Ltd - CMMB EV/Sales Multiple

Public company logo of Chemomab Therapeutics Ltd (CMMB)

Israeli biopharm developer Chemomab Therapeutics (CMMB) relies on unique antibodies to combat inflammation. The business valuation based on EV/Sales reflects the market reaction to these studies, where the 0.00 figure expresses the state of the metric. An innovative method for combating tissue scarring offers hope for fatal pathologies, although high clinical trial costs exert significant financial pressure on Chemomab Therapeutics (CMMB).

Chemomab Therapeutics Ltd. - CMMB Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

Chemomab Therapeutics Ltd. - analytical breakdowns and key metrics (CMMB)

Fundamental company valuation:Chemomab Therapeutics Ltd CMMB
Mass-produced product of chemomab.com

The absence of debt obligations and the patent protection of CM-101 create a unique foundation of resilience, which is reflected in the Chemomab Therapeutics (CMMB) enterprise value-to-revenue trajectory. This indicator compares the total market value of the business with its operating income, excluding the impact of leverage, allowing investors to assess the actual premium paid for every ruble of revenue without distortions from the capital structure.